An observational study in Knee Osteoarthritis, sponsored by Kang Stem Biotech Co., Ltd.. Recruiting at 2 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.
Sponsored by Kang Stem Biotech Co., Ltd. · Observational
Among 96 studies in Osteoarthritis, Knee with a site in Korea, Republic of — 13 open to participants now, 21 under way, 4 of them phase 3. Osteoarthritis, Knee · Korea, Republic of.
Among the 96 studies in Osteoarthritis, Knee with a site in Korea, Republic of, this one is the 9th largest by planned enrollment of the 11 observational ones that give a count, is one of 5 that started in 2026, is one of 11 observational ones, reaches primary completion later than 20 of the 20 other live ones, and was the 92nd registered.
3,292 studies on the registry are indexed under Osteoarthritis, Knee; 621 are open to participants now.
Browse Osteoarthritis, Knee studies →13 of the 96 studies in Osteoarthritis, Knee with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Yonsei University · Sites in Korea, Republic of
Ages 40–75
Yonsei University · Sites in Korea, Republic of
Ages 40–70
Yonsei University · Sites in Korea, Republic of
Ages 19+
Glaceum · Sites in Korea, Republic of
Ages 40–75
Endovision Co., Ltd. · Sites in Korea, Republic of
Ages 40–80
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 382 Osteoarthritis, Knee studies recruiting now, 176 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
96 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 21 · Phase 3 20 · Phase 4 17
First in 2005; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 36 is below the median of 100 across 486 observational studies indexed under Osteoarthritis, Knee.
Median enrollment 124 across the 85 interventional studies, 50 across the 11 observational. Of the 54 that completed or were terminated, 9 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
54 of 96 have an industry lead sponsor. The 10 most frequent:
Kang Stem Biotech Co., Ltd. is the lead sponsor of 19 studies on the registry; 5 are open to participants now.
Kang Stem Biotech Co., Ltd. has 3 studies filed under Osteoarthritis, Knee — fewer than ten, so there is no comparison to draw.
6 of the studies in Osteoarthritis, Knee with a site in Korea, Republic of that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04427930Phase 3R-BioFollow-up Study for Participants of Jointstem Phase 3 Clinical Trial | 2026-12-23 |
| NCT04368806Phase 3Nature Cell Co. Ltd.A Phase 2b/3a Study to Evaluate the Efficacy and Safety of JointStem in Patients Diagnosed as Knee Osteoarthritis | 2027-08-06 |
| NCT07267793DALIM TISSEN Co., Ltd.Long-Term Study of CartiPRO for Knee Pain Due to Osteoarthritis or Cartilage Damage | 2026-12 |
| NCT07367789Yonsei UniversityPrediction of Postoperative Outcomes After TKA Using Instrumented Insoles and DNN | 2026-12-31 |
| NCT06798727Medipost Co Ltd.Evaluation Safety and Explore Efficacy Long-term Follow-up Study on Subjects Receiving SMUP-IA-01 or Active Control | 2027-03-20 |
Add all 6 to your calendar (.ics) → With an account.
Among the 96 studies in Osteoarthritis, Knee with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Multicenter, Open-Label, Single-Arm Extension Study to Evaluate the Safety and Efficacy of FURESTEM-OA-Kit Inj. in Knee Osteoarthritis Patients Who Received Placebo in the K0701 Phase 2a Trial
Participants who received placebo in the K0701 clinical trial, completed the long-term follow-up study, and voluntarily provided written informed consent to participate in this extension study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants meeting any of the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Incidence of Adverse Event, AESI(Adverse Event of Special Interest)
Time frame: 5 years follow-up after treatment
Changes in Knee Injury and Osteoarthritis Outcome Score (KOOS)
Time frame: Month 3, Month 6, Month 12, Month 24, Month 60 after treatment
Changes in Western Ontario and McMaster Universities osteoarthritis index (WOMAC)
Time frame: Month 3, Month 6, Month 12, Month 24, Month 60 after treatment
Changes in 100-mm VAS
Time frame: Month 3, Month 6, Month 12, Month 24, Month 60 after treatment
Changes in International Knee Documentation Committee Scoring System (IKDC)
Time frame: Month 3, Month 6, Month 12, Month 24, Month 60 after treatment
Evaluation of International K&L grade(X-ray)
Time frame: Month 12, Month 24 after treatment
Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) scores(MRI)
Time frame: Month 12, Month 24 after treatment
Whole-Organ Magnetic Resonance Imaging Score (WORMS) score
Time frame: Month 12, Month 24 after treatment
Started Jul 2026 (actual). Primary completion is estimated for Dec 2031, 65 months after the start.
Of 220 observational studies under Osteoarthritis, Knee, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 61. This study's planned 65 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kang Stem Biotech Co., Ltd.